[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,105
  • Shares Outstanding, K 31,146
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -22,700 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta -0.35
  • Price/Sales 16.50
  • Price/Cash Flow N/A
  • Price/Book 0.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.13
  • Most Recent Earnings $-0.19 on 05/13/26
  • Next Earnings Date 08/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 3
  • High Estimate $-0.18
  • Low Estimate $-0.21
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +42.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5949 +4.56%
on 07/17/26
0.8650 -28.09%
on 06/18/26
-0.2180 (-25.95%)
since 06/17/26
3-Month
0.5949 +4.56%
on 07/17/26
1.1199 -44.46%
on 04/20/26
-0.4780 (-43.45%)
since 04/17/26
52-Week
0.4750 +30.95%
on 03/06/26
1.8000 -65.44%
on 07/21/25
-0.9180 (-59.61%)
since 07/17/25

Most Recent Stories

More News
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Marie Washburn as Chief Financial Officer

Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Present at BIO International Convention 2026

Company will highlight new and recently published data for stem cell therapy laromsestrocel Focus on potential partnership and strategic opportunities for Hypoplastic Left Heart Syndrome, Alzheimer’s...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment,...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 0.6673
2nd Resistance Point 0.6474
1st Resistance Point 0.6347
Last Price 0.6220
1st Support Level 0.6021
2nd Support Level 0.5822
3rd Support Level 0.5695

See More

52-Week High 1.8000
Fibonacci 61.8% 1.2938
Fibonacci 50% 1.1375
Fibonacci 38.2% 0.9811
Last Price 0.6220
52-Week Low 0.4750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.